SNPMiner Trials (Home Page)
Report for SNP rs12255372
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure
This study evaluates the link between genetic polymorphisms as r7903146, rs12255372 of TCF7L2 gene and the risk of developing hyperglycemia during Intensive care unit stay
NCT03055169 Genetic Predisposition to Disease Hyperglycemia Intensive Care Unit Syndrome Multiple Organ Failure Genetic: genetic analysis Biological: blood and stools samples MeSH:Hyperglycemia Disease Susceptibility Genetic Predisposition to Disease Multiple Organ Failure
HPO:Hyperglycemia Postprandial hyperglycemia
TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure This study evaluates the link between genetic polymorphisms as r7903146, rs12255372 of TCF7L2 gene and the risk of developing hyperglycemia during Intensive care unit stay value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of hyperglycemia.
Primary Outcomes
Description: find a link between genetic polymorphism of TCF7L2 and the risk of developing hyperglycemia in intensive care patients with a least one organ dysfunction. the hyperglycemia is defined fasting glucose> 1.26 g / l twice or need for treatment with insulin)
Measure: value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of hyperglycemia Time: one year after inclusionSecondary Outcomes
Measure: Changes in inflammatory markers Time: one year after inclusionDescription: Changes in cholesterol total, LDL cholesterol, HDL cholesterol and triglycerides
Measure: Changes in serum lipid profile Time: one year after inclusionDescription: Changes in total alanine transaminase (ALT) total gamma-GT total aspartate transaminase (AST)
Measure: Changes in liver enzymes Time: one year after inclusionDescription: Calculated using the updated homeostasis model assessment (HOMA) calculator.Higher numbers indicate higher insulin resistance. There are no established cutoffs indicating impaired resistance.
Measure: Insulin Resistance (HOMA) Time: one year after inclusionOther Outcomes
Description: the blood samples collection will created for next research Both on diabetes and / or insulin resistance as its determinisms, at the ICU patient
Measure: Blood samples collection Time: 5 yearsDescription: the prevalence of TCF7L2, in the intensive care patient or not glycemic control, and compared to the values found in the general population. the TCF7L2 genes will be evaluated by the Taqman method (7900HT Fast Real-Time PCR System-Applied BioSystem).
Measure: Number of patients with genotype TCF7L2 by PCR Time: 5 years